8-K: ENDRA Life Sciences Regains Nasdaq Compliance

ENDRA Life Sciences Inc. announced it believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement following a $4.9 million private placement and other strategic actions.

Summary

• ENDRA Life Sciences Inc. received a Nasdaq notification on May 27, 2025, for falling below the $2.5 million minimum stockholders' equity requirement.
• The company submitted a compliance plan on July 11, 2025, and was granted an extension until November 24, 2025, to regain compliance.
• On October 15, 2025, ENDRA closed a private placement offering, raising approximately $4.9 million through the sale of 744,340 shares and warrants for up to 1,488,680 shares.
• The company launched a digital asset treasury strategy on October 23, 2025, by purchasing 78,863.1 HYPE tokens.
• An At-The-Market (ATM) Issuance Sales Agreement was entered into on October 29, 2025, allowing the sale of up to $1,750,000 in common stock.
• As of November 14, 2025, ENDRA believes it has regained compliance with Nasdaq's $2.5 million stockholders' equity rule.
• Nasdaq will continue to monitor compliance, and failure to evidence compliance in the next periodic report could lead to delisting.

Sentiment

Score: 6

Explanation: The company successfully addressed an immediate delisting threat by raising capital and believes it has regained Nasdaq compliance. However, the underlying issues of limited cash, history of losses, and the new, potentially volatile digital asset strategy introduce ongoing risks and uncertainties. The compliance is still subject to Nasdaq's ongoing monitoring.

Positives

• Successfully raised approximately $4.9 million through a private placement offering.
• Believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement, avoiding immediate delisting.
• Established an At-The-Market (ATM) facility for potential future capital raises of up to $1,750,000.

Negatives

• Previously fell below Nasdaq's minimum stockholders' equity requirement of $2.5 million.
• Nasdaq will continue to monitor compliance, and future non-compliance could still lead to delisting.
• The company has limited commercial and digital asset treasury (DAT) experience, limited cash, and a history of losses.

Risks

• Uncertainty regarding the digital asset treasury (DAT) strategy and the company's ability to execute it successfully.
• Limited commercial and DAT experience, limited cash, and a history of losses.
• Inability to obtain adequate financing to fund business operations or the DAT strategy in the future.
• Risks related to the treatment of crypto assets for U.S. and foreign tax purposes.
• Regulatory developments related to crypto assets and crypto asset markets.
• A determination that the company is an investment company under the Investment Company Act of 1940.
• Any changes in the accounting treatment of cryptocurrency holdings.
• Inability to maintain compliance with Nasdaq's requirement to have a minimum of $2,500,000 in stockholders' equity for continued listing.
• Other risks and uncertainties described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.

Future Outlook

The company anticipates that its digital asset treasury strategy will be successfully executed. However, it acknowledges risks related to its limited commercial and DAT experience, cash position, and ability to secure future financing. Nasdaq will continue to monitor the company's compliance with the stockholders' equity requirement, and failure to evidence compliance in the next periodic report could lead to delisting.

Management Comments

• We believe we have regained compliance with the minimum $2.5 million stockholders' equity requirement for continued listing as set forth in the Rule.

Industry Context

This announcement reflects a common challenge for smaller life sciences companies, particularly those with limited commercialization, in maintaining Nasdaq listing standards. The adoption of a digital asset treasury strategy, while potentially innovative, introduces new financial and regulatory complexities not typically seen in traditional life sciences operations, potentially diversifying risk but also adding new layers of uncertainty.

Comparison to Industry Standards

• NA

Related Party Transactions

• A member of the company's board of directors purchased warrants in the private placement offering at an exercise price of $6.81, compared to $6.32 for other investors.

Stakeholder Impact

• Shareholders: The private placement and ATM offering could lead to dilution. Regaining Nasdaq compliance is positive for shareholder value by preventing delisting, but ongoing monitoring and underlying financial challenges remain. The digital asset strategy introduces new risk/reward profiles.
• Creditors: Improved financial position due to capital raise may reduce immediate credit risk, but long-term viability depends on sustained compliance and operational success.
• Employees: Continued listing on Nasdaq provides stability, but the company's limited cash and history of losses could still impact job security or growth opportunities.

Next Steps

• Nasdaq will continue to monitor the company's ongoing compliance with the stockholders' equity requirement.
• The company must evidence compliance at the time of its next periodic report to avoid potential delisting.
• Potential future sales of common stock through the At-The-Market (ATM) Issuance Sales Agreement for up to $1,750,000.

Key Dates

Recommendation

While ENDRA Life Sciences has taken crucial steps to regain Nasdaq compliance by raising capital, the underlying financial challenges, including a history of losses and limited cash, persist. The introduction of a digital asset treasury strategy adds a new layer of risk and uncertainty, given the volatility of crypto assets and regulatory complexities. The company's compliance is still subject to ongoing Nasdaq monitoring. Investors should hold to observe sustained compliance and the efficacy of the new strategies before making further commitments, as significant risks remain despite the immediate resolution of the delisting threat.

Keywords

ENDRA Life Sciences, NDRA, Nasdaq compliance, stockholders equity, private placement, capital raise, digital asset treasury, HYPE tokens, ATM offering, delisting risk, financial health, SEC filing, 8-K